Published in final edited form as:

Biochemistry. 2013 April 16; 52(15): 2597–2608. doi:10.1021/bi301461t.

Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM)-mediated Inhibitory Signaling is Regulated by Sequential Phosphorylation Mediated by Distinct Nonreceptor Tyrosine Kinases: A Case Study Involving PECAM-1

Benjamin E. Tourdot^{1,2}, Michelle K. Brenner¹, Kathleen C. Keough¹, Trudy Holyst¹, Peter J. Newman^{1,2,3}, and Debra K. Newman^{1,2,4,*}

¹Blood Research Institute, BloodCenter of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

²Department of Pharmacology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

³Department of Toxicology, Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

⁴Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Abstract

The activation state of many blood and vascular cells is tightly controlled by a delicate balance between receptors that contain immunoreceptor tyrosine-based activation motifs (ITAMs) and those that contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Precisely how the timing of cellular activation by ITAM-coupled receptors is regulated by ITIM-containing receptors is, however, poorly understood. Using platelet endothelial cell adhesion molecule 1 (PECAM-1) as a prototypical ITIM-bearing receptor, we demonstrate that initiation of inhibitory signaling occurs via a novel, sequential process in which Src family kinases phosphorylate the C-terminal ITIM, thereby enabling phosphorylation of the N-terminal ITIM of PECAM-1 by other Src homology 2 domain-containing non-receptor tyrosine kinases (NRTKs). NRTKs capable of mediating the second phosphorylation event include C-terminal Src kinase (Csk) and Bruton's tyrosine kinase (Btk). Btk and Csk function downstream of phosphatidylinositol 3-kinase (PI3K) activation during ITAM-dependent platelet activation. In ITAM-activated platelets that were treated with a PI3K inhibitor, PECAM-1 was phosphorylated but did not bind the tandem SH2 domain-containing tyrosine phosphatase SHP-2, indicating that it was not phosphorylated on its N-terminal ITIM. Csk bound to and phosphorylated PECAM-1 more efficiently than did Btk, and required its SH2 domain to perform these functions. Additionally, the phosphorylation of the N-terminal ITIM of Siglec-9 by Csk is enhanced by the prior phosphorylation of its C-terminal ITIM, providing evidence that the ITIMs of other dual ITIM-containing receptors are also sequentially phosphorylated. On the basis of these findings, we propose that sequential ITIM phosphorylation provides a general mechanism for precise temporal control over the recruitment and activation of tandem SH2 domain-containing tyrosine phosphatases that dampen ITAM-dependent signals.

*Corresponding Author: Debra.Newman@bcw.edu; TEL: 414-937-3820; Fax: 414-937-6284.

This material is available free of charge via the Internet at <http://pubs.acs.org>.

Multi-subunit immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors are commonly used to activate hematopoietic cells. Such receptors include the T cell receptor (TCR), the B cell receptor (BCR), receptors for the Fc portions of IgE and IgG on mast cells and natural killer cells, respectively, killer cell immunoglobulin-like and lectin-like receptors, and the glycoprotein VI (GPVI) collagen receptor on platelets.^{1,2} The ligand binding components of each receptor are coupled to ITAM-containing signaling subunits, including the TCR ζ chain and CD3 subunits, BCR Ig α and β subunits, the FcR γ chain, and DAP-12. In each case, members of three families of non-receptor tyrosine kinases (NRTK), including Src family kinases (SFK), spleen tyrosine kinases (Syk), and Tec family kinases, execute an ordered series of tyrosine phosphorylation events that ultimately result in cell activation.

Two types of inhibitory processes regulate cellular activation by ITAM-coupled receptors. The first of these is mediated by members of the C-terminal Src kinase (Csk) family, which phosphorylate the tyrosine residue at the C-terminus of SFKs, thereby enabling an intramolecular association that suppresses SFK activity.^{1,3} The ability of Csk to inhibit ITAM-dependent signal transduction requires binding of its SH2 domain to phosphotyrosine residues in Csk binding proteins (Cbp), which are themselves substrates for phosphorylation by SFKs. SH2 domain-dependent binding of Csk to Cbp has two outcomes that are important for suppression of SFK activity: first, it enables recruitment of Csk to sites of SFK activity, and second, it results in a dramatic increase in kinase activity toward its substrates.^{3,4}

The second mechanism involved in regulation of cellular activation by ITAM-coupled receptors is mediated by immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing inhibitory receptors. These receptors constitute a large family of molecules that includes immunoglobulin (Ig) superfamily members, sialic acid binding lectin-like molecules (Siglecs), and C-type lectin receptors.^{1,5,6} Inhibition of ITAM-mediated signaling by ITIM-containing receptors requires phosphorylation of ITIM tyrosine residues, which enables recruitment and activation of SH2 domain-containing inositol and tyrosine phosphatases that, upon binding, interfere with signaling by ITAM-coupled receptors. Most ITIM-containing inhibitory receptors contain two ITIMs that, upon phosphorylation, bind the tandem SH2 domain-containing tyrosine phosphatases, SHP-1 and SHP-2. SFK activity is required for ITIM tyrosine phosphorylation; however, the precise phosphorylation events for which SFKs are required are not known.⁷⁻⁹ Furthermore, whether additional enzymes function to control the initiation of inhibitory relative to activating signaling has not been explored.

Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) is a dual ITIM-containing receptor of the Ig superfamily that is capable of inhibiting ITAM-induced activation of B cells, T cells, and mast cells, but whose best-characterized function is inhibition of GPVI/FcR γ chain-mediated platelet activation.¹⁰ The inhibitory properties of PECAM-1 require phosphorylation of both of its ITIMs, which surround tyrosine residues at positions 663 (VQY663TEV) and 686 (TVY686SEV) of human PECAM-1, and recruitment of SHP-2 or, less efficiently, SHP-1. The ITIMs of PECAM-1 are not phosphorylated in resting cells, but are phosphorylated upon cellular activation in a manner that depends on SFK activity. In platelets, PECAM-1 inhibitory function depends on the SFK, Lyn;¹¹ however, other NRTKs have been shown to mediate PECAM-1 ITIM phosphorylation, including Feline sarcoma-related (Fer)/Fujinami poultry sarcoma (Fps) family kinases and Csk.¹²⁻¹⁴ The precise phosphorylation events for which these enzymes are responsible are not known. We recently reported that the PECAM-1 ITIMs are phosphorylated sequentially, with phosphorylation of Y₆₆₃ depending on prior phosphorylation of Y₆₈₆.¹⁵ This finding suggests that phosphorylation of dual ITIM-containing receptors proceeds via a two-step process in which

the second step requires SH2 domain-dependent interactions of a NRTK with an initially phosphorylated tyrosine residue. In the present study, we explore the roles of different SH2 domain-containing NRTKs known to be involved in ITIM/ITAM signaling in sequential phosphorylation of the PECAM-1 ITIMs. We demonstrate that SFKs efficiently mediate phosphorylation of the C-terminal ITIM, but that the N-terminal ITIM is phosphorylated by distinct NRTKs in a manner that requires SH2 domain-dependent interactions with the initially phosphorylated ITIM. We propose that a two-step, two-enzyme mechanism for dual ITIM phosphorylation allows inhibitory signaling to be temporally regulated so as to ensure optimal timing of control over cellular activation.

MATERIALS AND METHODS

Kinases

Recombinant kinases were purchased from commercial vendors: Btk and Lyn were obtained from Invitrogen (Calsbad, CA) and Csk from Sigma Aldrich (St. Louis, MO).

Peptide synthesis

Peptides were synthesized using standard Fmoc protocols on an ABI 433 instrument. Phosphotyrosine was coupled as Fmoc-Tyr(PO(OBzl)OH)-OH (EMD Millipore chemicals). The SH2 domain optimal binding peptides were synthesized as amides while the PECAM peptides were synthesized as free acids. The peptide resin was cleaved with 92.5% TFA: 2.5% EDT: 2.5% TIS: 2.5% H₂O and precipitated in cold ethyl ether. The peptides were purified to >90% by RP-HPLC using a Phenomenex Proteo C12 column and a 0.1% TFA / acetonitrile gradient. The mass of final product was verified by MALDI-TOF mass spec analysis.

In vitro kinase assays

The ADP Hunter kit (DiscoverX Corporation, Fremont, CA) was used according to manufacturer's specifications. Briefly, recombinant kinases were incubated with synthetic peptides in kinase assay buffer I (50mM Tris, 1mM EGTA, 10mM MgCl₂, 0.01 % Brij35, 1mM DTT, 25 μ M ATP), and neutralization buffer (provided in kit) for four hours at 30°C. Reagents added to each well generate a fluorescence signal that is directly proportional to the amount of ADP produced. The amount of ADP produced during each reaction was quantified against an ADP standard curve (0 - 25 μ M). Fluorescence detected in kinase only wells accounted for ADP generated by non-enzymatic hydrolysis of ATP or baseline auto-phosphorylation of the kinase and was subtracted as background from peptide-containing wells.

Measurement of ³²P-incorporation into biotinylated, synthetic peptides was performed as previously described.¹⁶ All reactions were performed in kinase assay buffer I at 37°C for one hour (except as noted) in the presence of 0.1 μ Ci/ μ l [γ -³²P] ATP (6000mCi/mmol, Perkin Elmer). The reaction mixture was placed on ice and an equal volume of 2 mM unlabeled ATP was added to quench the reaction. The quenched reaction was added to 0.5 ml PBS containing 50 μ l of a 50% slurry of streptavidin-conjugated agarose beads (Pierce) and rotated for two hours at room temperature. Streptavidin beads were pelleted by centrifugation, washed five times in PBS, and added to 3 ml of scintillation fluid. Radioactivity incorporated into bead-bound substrate peptides was counted on a Wallac 1410 liquid scintillation counter (Perkin Elmer).

Phosphorylation of the PECAM-1 cytoplasmic domain

Recombinant forms of the PECAM-1 cytoplasmic domain (WT, Y₆₆₃F, and Y₆₈₆F) were generated and purified as previously described.¹⁵ To exclude the possibility of non-ITIM

tyrosine phosphorylation, sequences within the constructs that encoded non-ITIM tyrosine residues and that were predicted to serve as potential SFK phosphorylation sites (Y₆₃₆ and Y₇₀₁) were mutated so as to encode phenylalanine residues. Lyn (68 nmole/min activity in 25 μ l) was incubated with 1mM of the PECAM-1 cytoplasmic domain (PECAM-1_{cyto}) in kinase assay buffer II (250 μ M ATP, 1mM EGTA, 10mM MgCl₂, 0.01% Brij 35, and 250 μ M Na₃VO₄) for 10 minutes at 30°C and then heated to inactivate Lyn. Btk, Csk or Lyn were then added to the reaction mixture along with additional ATP (250 μ M). These reactions were carried out for an additional 30 minutes at 30°C, stopped by boiling after addition of an equal volume of 2X SDS-PAGE sample reducing buffer, separated on a 12% SDS-polyacrylamide gel and stained with Coomassie. Band intensities were measured using a Kodak molecular imaging densitometry system.

Peptido-precipitation from platelet lysate

Platelets were isolated from healthy human volunteers as previously described.¹⁷ The platelets were resuspended in Tyrode's buffer (137 mM NaCl, 20 mM HEPES, 13.8 mM NaHCO₃, 2.5 mM KCl, 0.36 mM NaH₂PO₄, 0.25% BSA, and 0.1% glucose) to a final concentration of 5 $\times$ 10⁸ platelets/ml and lysed with an equal volume of 2X lysis buffer (30 mM HEPES, 300 mM NaCl, 20mM EGTA, 0.2 mM MgCl₂, 2% Triton X-100) containing 2X Phosphatase Inhibitor Cocktail Set II, and Protease Inhibitor Cocktail Set I (EMD Millipore). The cytoskeleton was removed from the platelet lysate by centrifugation at 4°C for 15 minutes at 14,000 $\times$ g. Biotinylated PECAM-1 peptides (Y₆₆₃,F₆₈₆ or Y₆₆₃,pY₆₈₆) were immobilized on streptavidin sepharose beads (Pierce) and washed twice to remove excess peptide. The peptide-bead complex was then added to the platelet lysate and incubated overnight at 4 °C with constant mixing. The beads were washed five times with 1X lysis buffer, resuspended in 2X SDS-PAGE sample buffer and boiled. Proteins eluted from the beads were separated on a 4–20% SDS-PAGE gel and identified by Western blot analysis.

Expression and purification GST-tagged proteins

Glutathione S-transferase (GST)-conjugated forms of Csk were expressed and purified as described in Yaqub, *et. al.*¹⁸ Briefly, full-length Csk was amplified from pDONR223-Csk (A gift from William Hahn and David Root, Addgene plasmid #23941) and ligated into the pGEX-KG vector to encode a GST-Csk fusion protein. Point mutations encoding substitutions of lysine for arginine at position 107 (R₁₀₇K) or of cysteine for serine at position 109 (S₁₀₉C), which have previously been shown to abolish phosphotyrosine binding by the Csk SH2 domain,^{19,20} were made using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). GST fusion proteins were expressed in BL21 (DE3) cells (Invitrogen), and induced with 1mM IPTG for 3 hours at 37°C. The bacterial pellet was resuspended in 20 ml PBS, 1mM Pefabloc, and 0.1% Triton X-100 per liter of cells and sonicated. After clarification by centrifugation, the lysate was passed over glutathione sepharose 4 Fast Flow (GE Healthcare) and eluted with 50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0. Purified kinases were stored in 20 mM Tris, pH 7.4, 1 mM EDTA, 1mM DTT, and 50% glycerol at –20°C. Purified isolated SH2 domains were stored in 20 mM Tris pH 7.4.

The plasmid encoding the SH2 domain of Lyn was a generous gift Osamu Miura. The isolated SH2 domain of Btk was amplified from full length Btk in a pDONR223 vector (A gift from William Hahn and David Root, Addgene plasmid #23918). Sequences encoding the Lyn and Btk SH2 domains were ligated into the GST containing vector, pGEX-KG. Expression and purification of the GST-fusion proteins containing the SH2 domains of these enzymes was performed as previously described for the GST-fusion protein containing the SH2 domain of Csk.²⁶

Flow cytometry bead-based binding assay

Binding of full-length Lyn, Btk and Csk as well as of their isolated SH2 domains to phosphopeptides corresponding to the C-terminal ITIM of PECAM-1 was assessed using a flow cytometry bead-based binding assay. To assess the ability of the isolated SH2 domains to bind to PECAM-1 phosphopeptides, biotinylated PECAM-1 peptides were incubated with streptavidin-coated polystyrene particles (SVP-60-5, Spherotech) in PBS containing 0.2% BSA (PBS/0.2% BSA) for 45 minutes at room temperature and the peptide-bead complex was washed once with PBS/0.2% BSA. Recombinant GST-fusion proteins containing the SH2 domains of Lyn, Btk or Csk were incubated with the peptide-bead complex for two hours at room temperature and washed once with PBS/0.2% BSA. An Alexa Fluor-647-conjugated GST-specific antibody was then incubated with the beads and washed once with PBS/0.2% BSA. Beads were analyzed by flow cytometry using an LSR II (Becton Dickinson) high throughput sampler and median fluorescence intensities (MFI) were recorded.

To assess the ability of WT, R₁₀₇K, and S₁₀₉C forms of full-length Csk to bind to a phosphopeptide corresponding to the PECAM-1 C-terminal ITIM, Protein G-coated polystyrene particles (PGP-60-5, Spherotech) were incubated with a Csk-specific antibody (SC-286, Santa Cruz) in PBS/0.2% BSA at room temperature for 30 minutes. The beads were washed twice with PBS/0.2% BSA, after which WT, R₁₀₇K, or S₁₀₉C forms of GST-Csk (10 µg) were added and incubated 30 minutes at room temperature. Beads were washed once with 1M NaCl and twice with PBS/0.2% BSA. Biotinylated PECAM-1 Y₆₆₃P Y₆₈₆ (10 µM) was incubated with Csk-coated beads for 30 minutes at room temperature and washed once with PBS/0.2% BSA. Alexa Fluor-647-conjugated streptavidin (3 µg/ml; Molecular Probes) was then incubated with the beads for 30 minutes at room temperature, after which beads were washed once with PBS/0.2% BSA. Flow cytometry was performed as described above and median fluorescence intensities (MFI) were recorded.

Characterization of PECAM-1 immunoprecipitated from platelet lysates

Platelets were isolated from healthy human volunteers as previously described.¹⁷ Platelets were resuspended in Tyrode's buffer (7.5×10⁸/ml) and were supplemented with 1mM CaCl₂ immediately prior to stimulation. Platelets suspensions were stimulated with collagen-related peptide (CRP; 5µg/ml) with stirring in a lumi-aggregometer (Chronolog) in the presence or absence of a PI3K inhibitor (TGX-221; Santa Cruz) to block downstream recruitment and activation of Btk and Csk, and of a SHP-2 inhibitor (NSC-87877; Santa Cruz) to block de-phosphorylation of singly-phosphorylated forms of PECAM-1. Platelets were lysed with 2X lysis buffer for one hour at 4°C, after which the cytoskeleton was removed by centrifugation at 4°C for 15 minutes at 14,000 × g. PECAM-1 was immunoprecipitated from platelet lysates by overnight incubation at 4°C with PECAM-1.3-coated Protein G-sepharose beads. The beads were washed five times with 1X lysis buffer, resuspended in 2X SDS-PAGE sample buffer and boiled. Proteins eluted from the beads were separated on a 7.5% Bio-Rad TGX gel and analyzed by Western blot using antibodies specific for SHP-2(C-18; Santa Cruz), phosphotyrosine (4G10 platinum; Millipore), and PECAM-1(PECAM-1.3).

Statistical analysis

Statistically significant differences were identified by performing a one-way ANOVA followed by a Bonferroni post hoc test using GraphPad Prism 5 software.

RESULTS

Lyn, but not Btk or Csk, is a PECAM-1 C-terminal ITIM kinase

In platelets activated via the GPVI collagen receptor, Lyn is required for PECAM-1 ITIM phosphorylation and SHP-2 binding.¹¹ However, it is not known whether Lyn phosphorylates both of PECAM-1's two ITIMs or instead mediates initial phosphorylation of one ITIM tyrosine, which is then required for subsequent phosphorylation of the second ITIM tyrosine. To discriminate between these two possibilities, we incubated synthetic peptides corresponding to the N- and C-terminal ITIMs of PECAM-1 with recombinant, purified Lyn. Lyn robustly phosphorylated the Y₆₈₆-containing C-terminal ITIM peptide but not the Y₆₆₃-containing N-terminal PECAM-1 ITIM peptide (Figure 1A). These data indicate that Lyn is capable of mediating initial phosphorylation of the PECAM-1 C-terminal ITIM but that it cannot independently phosphorylate the PECAM-1 N-terminal ITIM.

Since Lyn was unable to phosphorylate the PECAM-1 N-terminal ITIM-containing peptide efficiently, we next sought to determine whether a different NRTK could act as the N-terminal ITIM kinase. The sequence preceding the target tyrosine residue (Y₆₆₃) in the N-terminal ITIM of PECAM-1 (NSDVQYTEV) conforms well to the motif in the C-terminal tail of SFKs that is targeted for phosphorylation by Csk.²¹ Therefore, we evaluated the ability of Csk to phosphorylate the N-terminal ITIM of PECAM-1. In addition, because Btk is closely related to Csk²² and has a prominent role in late stages of GPVI-mediated platelet activation,⁶ we also examined Btk for its ability to phosphorylate PECAM-1 Y₆₆₃. Interestingly, neither Btk nor Csk efficiently phosphorylated either Y₆₆₃- or Y₆₈₆-containing PECAM-1 peptides (Figure 1A), indicating that Btk and Csk are by themselves incapable of mediating either initial phosphorylation of C-terminal Y₆₈₆ or independent phosphorylation of N-terminal Y₆₆₃ of PECAM-1.

Phosphorylation of the PECAM-1 C-terminal ITIM enhances phosphorylation of the N-terminal ITIM by Btk and Csk

Phosphorylation of multiple sites within a single protein can occur in an interdependent manner, in which phosphorylation at a primary site enhances phosphorylation at a secondary site.²³ In the case of sequential *tyrosine* phosphorylation, the initially phosphorylated tyrosine residue can support SH2 domain-dependent interactions with either the same or a different NRTK, which enhances subsequent phosphorylation by maintaining the NRTK in an active conformation in close proximity to the second phosphorylation site.²³ Previous studies have shown that the SH2 domains of SFKs, Tec family kinases, and Csk are capable of binding to the phosphorylated C-terminal ITIM of PECAM-1.²⁴ To evaluate the relative abilities of these NRTKs to phosphorylate PECAM-1 N-terminal ITIM Y₆₆₃ in a manner that depends on prior phosphorylation of C-terminal ITIM Y₆₈₆, representative family members, including Lyn, Btk, and Csk, were incubated with Y₆₆₃-containing peptides that span both ITIMs and that contain either a phosphotyrosine (pY) or a phenylalanine (F) at position 686. As shown in Figure 1B, Lyn, Btk, and Csk were each able to phosphorylate PECAM-1 Y₆₆₃ in a peptide that contained a phosphotyrosine but not a phenylalanine at position 686; however, Btk and Csk were both much more efficient than was Lyn. Collectively, the results shown in Figure 1 suggest that Lyn is required for PECAM-1 inhibitory function because it mediates initial phosphorylation of the C-terminal ITIM. Subsequent phosphorylation of the N-terminal ITIM, which requires C-terminal ITIM phosphorylation, can be mediated by Lyn, but is more efficiently accomplished by other NRTKs, including Csk and Btk.

Initial phosphorylation of the PECAM-1 cytoplasmic domain by Lyn enables its subsequent phosphorylation by Btk or Csk

To determine whether observations made using synthetic peptides extend to the intact PECAM-1 cytoplasmic domain, a recombinant form of the PECAM-1 cytoplasmic domain (PECAM-1_{cyto}) was incubated sequentially with Lyn, followed by additional Lyn, Btk or Csk. Mono- and di-phosphorylated forms of PECAM-1_{cyto} generated in the *in vitro* kinase reaction were separated from one another and from unphosphorylated PECAM-1_{cyto} by SDS-PAGE as previously described.¹⁵ As shown in Figure 2A, Lyn, but not Btk or Csk, effectively converted PECAM-1_{cyto} from its unphosphorylated form to a species that was phosphorylated at a single site, as reflected by a slight upward shift in the apparent molecular weight of PECAM-1_{cyto}. Pre-incubation of PECAM-1_{cyto} with Lyn enabled Btk and Csk to phosphorylate PECAM-1_{cyto} at a second site, as reflected in an even greater upward shift in the apparent molecular weight of the di-phosphorylated species (Figure 2A). Quantitatively, addition of Btk or Csk to singly-phosphorylated PECAM-1_{cyto} resulted in a significant increase in the amount of dually phosphorylated PECAM-1_{cyto} (Figure 2B). In contrast, addition of Lyn to singly-phosphorylated PECAM-1_{cyto} resulted in only a slight, and not significant, increase in the amount of dually phosphorylated PECAM-1_{cyto}. These data demonstrate that Lyn mediates only initial phosphorylation of C-terminal ITIM Y₆₈₆, which then supports recruitment of Btk and/or Csk to carry out subsequent phosphorylation of N-terminal ITIM Y₆₆₃.

To confirm that phosphorylation of the C-terminal ITIM accounts for the first shift in apparent molecular weight of PECAM-1_{cyto}, we generated a mutant form of PECAM-1_{cyto} in which the C-terminal ITIM tyrosine was substituted with phenylalanine (Y₆₆₃F₆₈₆) and evaluated its ability to undergo a mobility shift on SDS-PAGE gels after exposure to conditions that support tyrosine phosphorylation. In the mutant Y₆₆₃Y₆₈₆F form of PECAM-1_{cyto}, the single and double shifts in apparent molecular weight that were observed upon incubation of wild-type PECAM-1_{cyto} (Y₆₆₃Y₆₈₆) with Lyn or with Lyn plus Btk or Csk were ablated (Figure 2C). These data highlight the importance of Y₆₈₆ as the initiator of PECAM-1 phosphorylation and confirm that neither Y₆₆₃ nor any other residue in the PECAM-1 cytoplasmic domain serves as a substrate for Lyn, Btk or Csk. As expected, substitution of the N-terminal ITIM tyrosine with phenylalanine (F₆₆₃Y₆₈₆) ablated the second but not the first shift in apparent molecular weight of PECAM-1_{cyto} (Figure 2C). On the basis of these findings, we conclude that Lyn phosphorylates only the C-terminal ITIM (Y₆₈₆) of PECAM-1 and that this phosphorylation event is required for subsequent phosphorylation of the N-terminal ITIM (Y₆₆₃) by Btk or Csk.

Evidence for sequential phosphorylation of PECAM-1 in platelets activated via the ITAM-coupled GPVI collagen receptor

The GPVI collagen receptor on platelets is coupled to the ITAM-containing Fc receptor γ chain (FcR γ).^{1,2} Platelet activation in response to binding of collagen to the GPVI/FcR γ complex involves an ordered series of events that includes activation of Lyn, recruitment and activation of PI3K, and subsequent recruitment and activation of Btk.^{6,25} Fibrinogen binding to activated platelets results in platelet aggregation, which is required for phosphorylation of paxillin family members that serve as Csk binding proteins that recruit Csk to the membrane to participate in inhibitory signaling.²⁶ Platelets stimulated via the GPVI/FcR γ complex in the presence of a PI3K inhibitor would therefore be expected to engage in SFK-mediated but not Btk- or Csk-mediated signaling events. Our model predicts that, under these conditions of platelet activation, Lyn would be able to phosphorylate the PECAM-1 C-terminal ITIM but subsequent phosphorylation of the N-terminal ITIM by Btk or Csk would be precluded. As shown in Figure 3, PECAM-1 immunoprecipitated from platelets stimulated with collagen related peptide (CRP), a GPVI/FcR γ -specific ligand, in

the presence of a PI3K inhibitor (TGX-221) was tyrosine phosphorylated, but was unable to co-immunoprecipitate SHP-2. Since phosphorylation of both ITIMs is required for SHP-2 binding,²⁷ this finding suggests that PECAM-1 is phosphorylated on *only* one ITIM under these conditions. These data are consistent with a sequential two-enzyme model of ITIM phosphorylation in which Lyn phosphorylates the C-terminal ITIM of PECAM-1 (Y₆₈₆) after which Btk or Csk, both of which are activated downstream of PI3K, phosphorylates the N-terminal ITIM (Y₆₆₃) and enables recruitment of SHP-2.

The roles of SH2 domain-dependent interactions in pY₆₈₆-dependent phosphorylation of Y₆₆₃ by Btk and Csk

Models for sequential tyrosine phosphorylation predict that an initially phosphorylated tyrosine residue serves as a docking site to recruit a secondary kinase, which then phosphorylates the secondary site.²³ Such a model requires that the initially phosphorylated tyrosine be contiguous with the secondary target tyrosine. To examine whether Btk and Csk act in this manner on the two ITIMs of PECAM-1, we provided these enzymes with Y₆₆₃ either on the same peptide as pY₆₈₆ (Y₆₆₃pY₆₈₆) or on a separate peptide (pY₆₈₆ + Y₆₆₃). As shown in Figure 4, pY₆₈₆ markedly enhanced phosphorylation of Y₆₆₃ by Btk and Csk only when in the same peptide as Y₆₆₃. These data demonstrate that pY₆₈₆ acts in *cis* to serve as a docking site that brings Csk and Btk into close proximity to Y₆₆₃ and enable its phosphorylation.

A second prediction of sequential phosphorylation models is that the SH2 domain of the secondary kinase binds to the primary phosphorylation site. In a previous SH2 domain profiling study, the SH2 domains of both Csk and Tec were shown to bind to PECAM-1 pY₆₈₆-containing peptides; the Lyn SH2 domain also bound, albeit weakly, to PECAM-1 pY₆₈₆-containing peptides in this study.²⁴ To confirm these findings relative to Lyn and Csk and to extend them to the Tec family kinase Btk, we evaluated the abilities of full-length enzymes and their isolated SH2 domains to bind to PECAM-1 pY₆₈₆-containing phosphopeptides. In concordance with previous findings, we found that the isolated SH2 domain of Lyn bound to pY₆₈₆; however, the SH2 domain of Csk bound approximately twice as efficiently as that of Lyn (Figure 5A). In contrast to its family member, Tec, however, the Btk SH2 domain bound poorly to PECAM-1 pY₆₈₆, if at all (Figure 5A). Consistent with these findings, we found that PECAM-1 pY₆₈₆-containing phosphopeptides were capable of pulling down full-length Csk and Lyn but not Btk from platelet lysates (Figure 5B). These findings indicate that Csk and Lyn, but not Btk, bind to PECAM-1 pY₆₈₆ via their SH2 domains.

The finding that the Csk SH2 domain binds directly to PECAM-1 pY₆₈₆ but that the Btk SH2 domain does not raises the question of the role that the SH2 domains of these enzymes play in their abilities to phosphorylate PECAM-1 Y₆₆₃ in a pY₆₈₆-dependent manner. To address this question, we evaluated the abilities of phosphopeptides known to bind optimally to the SH2 domains of Btk or Csk, referred to as SH2 domain optimal binding peptides (SH2 OBP), as well as a short PECAM-1 pY₆₈₆-containing peptide, to inhibit phosphorylation of the long PECAM-1 Y₆₆₃pY₆₈₆ substrate peptide. The Btk SH2 OBP (GDGpYEEISPLLL) corresponds to a sequence that binds to the Btk SH2 domain with high affinity,²⁸ while the Csk SH2 OBP (DKDHLpYSTVCK) corresponds to a sequence within the paxillin family member, Hic5, that binds with high affinity to the Csk SH2 domain.²⁹ As shown in Figure 6, phosphorylation of Y₆₆₃pY₆₈₆ by either Btk (Figure 6A) or Csk (Figure 6B) was significantly inhibited by addition of an excess of the appropriate OBP or of the pY₆₈₆-containing competitor peptide. None of the competitor peptides inhibited phosphorylation of Poly (Glu₄-Tyr), a substrate that does not require SH2 domain-dependent interactions for its phosphorylation, by Btk (Figure 6C) or Csk (Figure 6D) indicating that they do not directly inhibit kinase activity. Interestingly, both the PECAM-1 pY₆₈₆-containing peptide and the

Csk SH2 OBP significantly *enhanced* phosphorylation of Poly (Glu₄-Tyr) by Csk (Figure 6D), which is consistent with the known ability of ligation of the Csk SH2 domain to enhance its kinase activity.³ In contrast, the PECAM-1 pY₆₈₆-containing peptide also significantly enhanced phosphorylation of Poly (Glu₄-Tyr) by Btk, whereas the Btk SH2 OBP did not (Figure 6C). These findings are consistent with a model in which PECAM-1 pY₆₈₆ provides a docking site for the SH2 domain of Csk, which both tethers the enzyme to the PECAM-1 cytoplasmic domain and stimulates enzymatic activity so as to ensure efficient phosphorylation of the N-terminal ITIM. In contrast, PECAM-1 pY₆₈₆ serves only an activating, and not a tethering, role for Btk, with activation appearing to occur via an SH2 domain independent mechanism.

To obtain direct evidence that the SH2 domain of Csk is required for its ability to phosphorylate Y₆₆₃ in a pY₆₈₆-dependent manner, we expressed wild-type (WT) and mutant forms of recombinant active Csk in which SH2 domain substitutions (S₁₀₉C and R₁₀₇K) that interfere with phosphotyrosine binding ability were introduced.^{19,20} We found that these substitutions either ablated (S₁₀₉C) or dramatically reduced (R₁₀₇K) Csk binding to PECAM-1 pY₆₈₆-containing phosphopeptides (Figure 7A). These substitutions had, however, either no effect (S₁₀₉C) or enhanced by 4-fold (R₁₀₇K) Csk-mediated phosphorylation of a non-SH2 domain-dependent substrate (Poly (Glu₄-Tyr); data not shown). As shown in Figure 7B, WT Csk robustly phosphorylated PECAM-1 Y₆₆₃ in a pY₆₈₆-dependent manner. In contrast, the R₁₀₇K substitution abolished, and the S₁₀₉C substitution dramatically reduced, Csk-mediated pY₆₈₆-dependent phosphorylation of Y₆₆₃. These findings strongly support a role for SH2 domain-dependent binding to PECAM-1 pY₆₈₆ in Csk-mediated phosphorylation of Y₆₆₃.

Siglec-9 ITIMs undergo sequential phosphorylation by Csk

The data presented thus far indicate that phosphorylation of the PECAM-1 ITIMs occurs via a two-step, two enzyme process. More specifically, our findings provide evidence that the first phosphorylation event, that of phosphorylation of the C-terminal ITIM (pY₆₈₆), is mediated by a SFK and that the enzyme most likely to carry out the second phosphorylation event, that of phosphorylation of the N-terminal ITIM, is Csk, which binds to and is activated by PECAM-1 pY₆₈₆. Interestingly, the PECAM-1 N-terminal ITIM (NSDVQYTEV) conforms perfectly to the consensus sequence that is known to be targeted by Csk,³ in that it possesses an acidic residue at the -3 position and glutamine residue at the -1 position relative to the target tyrosine residue. Among the dual ITIM-containing inhibitory receptors, Siglecs 7 (EREIQYAPL) and 9 (EGELQYASL) possess N-terminal ITIMs that conform perfectly to consensus sequences for phosphorylation by Csk.³⁰ We therefore sought to determine the extent to which our two-step model for sequential ITIM phosphorylation extends to other dual ITIM-containing inhibitory receptors by investigating the potential for Csk to sequentially phosphorylate the ITIMs of Siglec-9. Csk was incubated with two peptides, both of which span the two ITIMs of Siglec-9 and contain the N-terminal tyrosine residue (Y₄₁₆), but that differ from one another in that they contain either a phosphotyrosine (pY) or a phenylalanine (F) at the position of the C-terminal ITIM tyrosine residue (position 439). As shown in Figure 8, Csk was able to phosphorylate Siglec-9 Y₄₁₆ in a peptide that contained a phosphotyrosine but not a phenylalanine at position 439. These results demonstrate that N-terminal ITIM of Siglec-9 can serve as a substrate for phosphorylation by Csk, but only when the C-terminal ITIM of Siglec-9 is already phosphorylated, which supports a sequential mechanism for phosphorylation of this receptor.

DISCUSSION

ITAM-coupled receptors are utilized by virtually every type of hematopoietic cell to effect cellular activation.^{1,5,8} It is important that ITAM-mediated cellular activation be properly regulated to avoid pathological conditions such as autoimmunity, hypersensitivity, tumor progression, and occlusive thrombus formation. Two major mechanisms that regulate ITAM-coupled receptors include inhibition of SFK activity by Csk,^{1,3} and dephosphorylation of ITAM-coupled receptor signal transduction pathway components by tandem SH2 domain-containing tyrosine phosphatases recruited to dual ITIM-containing inhibitory receptors.¹ ITAM-dependent activation pathways and both Csk- and ITIM-mediated inhibitory pathways are initiated through SFK-mediated phosphorylation of tyrosine residues in ITAMs, Csk binding proteins, and ITIMs, respectively, which has led to the supposition that all of these pathways are engaged simultaneously, and that the magnitude of the cellular response is determined by the balance that is struck between activating and inhibitory signals.¹ In the present study, we describe a novel mechanism through which the timing of activation and inhibition can be controlled. Specifically, we use PECAM-1 and the signal transduction pathway that it regulates in platelets as a model system to characterize the mechanism by which cells exert precise control over the timing of initiation of inhibitory signaling; namely, that dual ITIM phosphorylation takes place in a two-step process (Figure 9) in which a SFK phosphorylates one ITIM, after which the second ITIM is phosphorylated by a different NRTK. Enzymes that efficiently carry out the second phosphorylation event include Csk and Btk, which are involved only in very late stages of ITAM-dependent platelet activation. Together, the findings that SFKs mediate only the first step of dual ITIM phosphorylation and that other NRTKs recruited only very late during ITAM-dependent cellular activation mediate the second step provide new insights into the mechanism by which ITIM-mediated inhibition can be delayed relative to ITAM-mediated activation so as to ensure proper timing of control over the cellular activation process.

SFK activity has been shown to be required for the phosphorylation of many ITIM-containing receptors.^{8,11;12;23–29} By defining in the present studies the precise phosphorylation event for which SFK activity is required in phosphorylation of PECAM-1, we demonstrate that SFK activity is necessary but not sufficient to initiate dual ITIM-containing inhibitory receptor function. Specifically, we found that SFKs phosphorylate only the C-terminal ITIM of PECAM-1, which in turn confers the ability to recruit a second ITIM kinase that phosphorylates the N-terminal ITIM. We chose to establish this principle using the SFK Lyn, since Lyn is known to inhibit ITAM-mediated cellular activation in several cell types and to be required for PECAM-1 phosphorylation and for PECAM-1-mediated inhibitory function in platelets.¹¹ The ability to phosphorylate only one of the two PECAM-1 ITIMs is, however, not unique to Lyn but extends to other SFKs as well (Supplemental Figure 1), many of which have been reported to phosphorylate PECAM-1 in cells other than platelets and to be involved in phosphorylation of other ITIM-containing receptors. The extent to which SFK activity is, in general, necessary but not sufficient for dual ITIM-containing inhibitory receptor function remains to be determined.

Our findings identify Lyn, Btk and Csk as three kinases that are able to phosphorylate PECAM-1 N-terminal ITIM Y₆₆₃ in a manner that depends on prior phosphorylation of C-terminal ITIM Y₆₈₆. Csk utilizes SH2 domain-dependent interactions with PECAM-1 pY₆₈₆ to support subsequent phosphorylation of Y₆₆₃, and Lyn appears to share this property with Csk. Thus, our findings suggest a possible physiologically relevant explanation for previously reported interactions of PECAM-1 with SFKs including Lyn.³¹ Nevertheless, the observation that the SH2 domain of Lyn domain binds PECAM-1 pY₆₈₆ less strongly than does that of Csk, coupled with the observation that pY₆₈₆-dependent phosphorylation of

Y₆₆₃ by Lyn is less efficient than is that by Csk suggests that, whereas Lyn is indeed able to bind PECAM-1 pY₆₈₆ and subsequently phosphorylate Y₆₆₃, Csk performs these functions more efficiently than does Lyn.

Csk has long been known to function as a PECAM-1 ITIM kinase.¹⁴ Our findings expand upon this early observation by demonstrating that Csk specifically phosphorylates the PECAM-1 N-terminal ITIM, but only when the C-terminal ITIM has already been phosphorylated by a SFK. Furthermore, we demonstrate that this function of Csk extends to a second dual ITIM-containing inhibitory receptor, specifically Siglec-9. Csk is well known for its ability to inhibit SFK-dependent signal transduction by phosphorylating the SFK C-terminal tyrosine residue, which enables an intramolecular inhibitory interaction with the SFK SH2 domain.^{1,3} An interesting conundrum in SFK biology is that the affinity of the intramolecular interaction between the SFK C-terminal phosphotyrosine residue and its SH2 domain is relatively low, such that a SFK will remain in an active conformation even after its C-terminal tail is phosphorylated if it is bound to a tyrosine phosphorylated protein that has higher affinity for the SFK SH2 domain.³² Csk binding proteins, which recruit Csk to sites of SFK activity, possess tyrosine-containing sequences that upon phosphorylation bind with high affinity to SFK SH2 domains, making it necessary for Csk binding proteins to be dephosphorylated for Csk-mediated inactivation of SFKs to be effective.³ Interestingly, SHP-2, which binds with high affinity to dually phosphorylated PECAM-1 and is an important mediator of its inhibitory function,^{33–36} has been implicated in dephosphorylation of two Csk binding proteins, specifically Cbp/PAG and paxillin.^{37,38} On the basis of these findings, we propose that Csk inhibits SFK-dependent signaling in two steps: first, by phosphorylating the C-terminal inhibitory tyrosine residue of the SFK and, second, by completing phosphorylation of a dual ITIM-containing inhibitory receptor and enabling binding of SHP-2. This proposed model explains how SHP-2 becomes available to dephosphorylate Csk binding proteins so as to enable SFK SH2 domains to *dissociate from activating intermolecular interactions* and instead *engage in inhibitory intramolecular interactions* with the tyrosine phosphorylated SFK C-terminal tail. Studies are underway in our laboratory to determine whether this function extends to other dual ITIM-containing receptors and to the SHP-2 homologue, SHP-1.

We found in the present studies that, like Csk, Btk is capable of phosphorylating the N-terminal ITIM of PECAM-1 in a manner that depends on prior phosphorylation of the C-terminal ITIM. When directly compared, however, Csk performed this function more efficiently than did Btk (Supplemental Figure 2), which suggests that Csk may be a more physiologically relevant PECAM-1 N-terminal ITIM kinase than is Btk. The mechanisms by which the phosphorylated C-terminal ITIM of PECAM-1 enhances phosphorylation of its N-terminal ITIM by Btk appears to differ from that utilized by Csk. Thus, whereas PECAM-1 pY₆₈₆ engages in SH2 domain-dependent interactions with Csk that both dock and activate the enzyme, this tyrosine phosphorylated sequence within PECAM-1 serves only to activate Btk and does support an SH2-dependent interaction with this enzyme. This finding was unexpected, given our observation that a peptide that binds optimally to the Btk SH2 domain inhibits pY₆₈₆-dependent phosphorylation of Y₆₆₃ and our previously published finding that the SH2 domain of the Btk homologue, Tec, does bind to peptides corresponding to the phosphorylated C-terminal ITIM of PECAM-1.²⁴ The mechanism used by Btk to phosphorylate the N-terminal ITIM of PECAM-1 may instead involve a remote substrate docking mechanism, which has previously been shown to be used by Tec family kinases to achieve substrate specificity.³⁹ This possibility remains to be tested. Finally, it is important to note that the primary function of Btk is to phosphorylate and activate PLCγ2 and thereby induce calcium mobilization downstream of ITAM-coupled receptor ligation.^{6,25} That this function is important is supported by the observations that mutations in the gene encoding Btk are responsible for X-linked agammaglobulinemia (XLA) in humans and X-linked

immunodeficiency in mice,⁴⁰ and that Btk deficiency results in profound platelet hyporesponsiveness to GPVI specific agonists in both humans and mice.^{41,42} It will ultimately be important to determine whether Btk has both stimulatory and inhibitory functions, and to evaluate the relative extents to which Btk and Csk are required for PECAM-1-mediated inhibitory functions, both of which issues can be resolved by studying the relative levels of responsiveness of cells derived from PECAM-1-positive and PECAM-1-deficient mice on a Btk-deficient⁴⁰ or conditionally Csk-deficient⁴³ background.

Studies of sequences within the PECAM-1 cytoplasmic domain that are required for efficient phosphorylation of its N-terminal ITIM by Lyn, Btk and Csk may also prove useful in attempts to engineer forms of PECAM-1 with enhanced inhibitory activity. Endowment of platelets with a potent dual ITIM-containing inhibitory receptor whose involvement in regulation of the platelet response can be delayed relative to ITAM-mediated activation would be expected to enable efficient control of bleeding with minimal complications due to pathological thrombus formation. Lessons learned from studies of sequential phosphorylation of the PECAM-1 ITIMs may also contribute to a better understanding of how other dual ITIM-containing receptors regulate the biological activities of a variety of hematopoietic cells that impact a large number of important disease processes, including autoimmunity, immediate-type hypersensitivity, and anti-tumor immunity.^{44–46}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by NIH grants HL90883 (D.K.N.), HL40926 (P.J.N.) and by the BloodCenter Research Foundation.

We thank Yan-Qing Ma for providing us with the methodology for the Flow cytometry bead-based binding assay. We also thank Amy Andreotti for helpful discussions.

The abbreviations used are

BCR	B-cell receptor
BLNK	B-cell linker protein
Btk	Bruton's tyrosine kinase
Cbp	Csk binding proteins
Csk	C-terminal Src kinase
DAG	diacylglycerol
FcRγ	Fc receptor γ -chain
Fer	Feline sarcoma-related
Fps	Fujinami poultry sarcoma
Gads	GRB2- related adapter protein 2
GPVI	glycoprotein VI
Ig	immunoglobulin
ITAM	immunoreceptor tyrosine-based activation motif
ITIM	immunoreceptor tyrosine-based inhibitory motif

IP3	inositol (1,4,5)-trisphosphate
LAT	linker for activation of T cells
Lyn	Lck/Yes-related novel protein tyrosine kinase
NRTKs	non-receptor tyrosine kinase
PECAM-1	platelet endothelial cell adhesion molecule 1
PI3K	Phosphatidylinositol 3-kinase
PIP₃	phosphatidylinositol 3,4,5- trisphosphate
PLCγ2	phospholipase C γ 2 isoform
SLP-76	Src homology 2 (SH2) domain- containing leukocyte protein of 76 kDa
SFK	Src family kinase
SHP-2	SH2 domain-containing protein tyrosine phosphatase 2
Siglecs	sialic acid binding lectin-like molecules
Syk	spleen tyrosine kinase
TCR	T cell receptor
XLA	X-linked agammaglobulinemia

References

1. Veillette A, Latour S, Davidson D. Negative regulation of immunoreceptor signaling. *Annu Rev Immunol.* 2002; 20:669–707. [PubMed: 11861615]
2. Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. *Immunol Rev.* 2007; 218:247–264. [PubMed: 17624957]
3. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. *Biochim Biophys Acta.* 2008; 1784:56–65. [PubMed: 17905674]
4. Takeuchi S, Takayama Y, Ogawa A, Tamura K, Okada M. Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. *J Biol Chem.* 2000; 275:29183–29186. [PubMed: 10918051]
5. Barrow AD, Trowsdale J. The extended human leukocyte receptor complex: diverse ways of modulating immune responses. *Immunol Rev.* 2008; 224:98–123. [PubMed: 18759923]
6. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. *J Thromb Haemost.* 2010; 8:1456–1467. [PubMed: 20345705]
7. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. *Immunol Rev.* 2008; 224:70–84. [PubMed: 18759921]
8. Ravetch JV, Lanier LL. Immune inhibitory receptors. *Science.* 2000; 290:84–89. [PubMed: 11021804]
9. Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. *Cold Spring Harb Perspect Biol.* 2011;3.
10. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular cell biology. *Arterioscler Thromb Vasc Biol.* 2003; 23:953–964. [PubMed: 12689916]
11. Ming Z, Hu Y, Xiang J, Polewski P, Newman PJ, Newman DK. Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation. *Blood.* 2011; 117:3903–3906. [PubMed: 21297004]
12. Udell CM, Samayawardhena LA, Kawakami Y, Kawakami T, Craig AW. Fer and Fps/Fes participate in a Lyn-dependent pathway from Fc ϵ RI to platelet-endothelial cell adhesion molecule 1 to limit mast cell activation. *J Biol Chem.* 2006; 281:20949–20957. [PubMed: 16731527]

13. Kogata N, Masuda M, Kamioka Y, Yamagishi A, Endo A, Okada M, Mochizuki N. Identification of fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cells. *Mol Biol Cell*. 2003; 14:3553–3564. [PubMed: 12972546]
14. Cao MY, Huber M, Beauchemin N, Famiglietti J, Albelda SM, Veillette A. Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of protein-tyrosine kinases. *J Biol Chem*. 1998; 273:15765–15772. [PubMed: 9624175]
15. Paddock C, Lytle BL, Peterson FC, Holyst T, Newman PJ, Volkman BF, Newman DK. Residues within a lipid-associated segment of the PECAM-1 cytoplasmic domain are susceptible to inducible, sequential phosphorylation. *Blood*. 2011; 117:6012–6023. [PubMed: 21464369]
16. Newman DK, Hoffman S, Kotamraju S, Zhao T, Wakim B, Kalyanaraman B, Newman PJ. Nitration of PECAM-1 ITIM tyrosines abrogates phosphorylation and SHP-2 binding. *Biochem Biophys Res Commun*. 2002; 296:1171–1179. [PubMed: 12207897]
17. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, Newman PJ. PECAM-1 negatively regulates GPIIb/IIIa signaling in murine platelets. *Blood*. 2003; 102:3658–3664. [PubMed: 12893757]
18. Yaqub S, Abrahamsen H, Zimmerman B, Kholod N, Torgersen K, Mustelin T, Herberg F, Taskén K, Vang T. Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain. *The Biochemical journal*. 2003; 372:271–278. [PubMed: 12600271]
19. Neet K, Hunter T. The nonreceptor protein-tyrosine kinase CSK complexes directly with the GTPase-activating protein-associated p62 protein in cells expressing v-Src or activated c-Src. *Molecular and cellular biology*. 1995; 15:4908–4920. [PubMed: 7544435]
20. Sabe H, Hata A, Okada M, Nakagawa H, Hanafusa H. Analysis of the binding of the Src homology 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src. *Proc Natl Acad Sci U S A*. 1994; 91:3984–3988. [PubMed: 7513429]
21. Wang D, Huang XY, Cole PA. Molecular determinants for Csk-catalyzed tyrosine phosphorylation of the Src tail. *Biochemistry*. 2001; 40:2004–2010. [PubMed: 11329267]
22. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science*. 2002; 298:1912–1934. [PubMed: 12471243]
23. Ruzzene M, Brunati AM, Marin O, Donella-Deana A, Pinna LA. SH2 domains mediate the sequential phosphorylation of HS1 protein by p72syk and Src-related protein tyrosine kinases. *Biochemistry*. 1996; 35:5327–5332. [PubMed: 8611520]
24. Machida K, Thompson CM, Dierck K, Jablonowski K, Karkkainen S, Liu B, Zhang H, Nash PD, Newman DK, Nollau P, Pawson T, Renkema GH, Saksela K, Schiller MR, Shin DG, Mayer BJ. High-throughput phosphotyrosine profiling using SH2 domains. *Mol Cell*. 2007; 26:899–915. [PubMed: 17588523]
25. Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. *Adv Immunol*. 2001; 79:93–128. [PubMed: 11680012]
26. Rathore VB, Okada M, Newman PJ, Newman DK. Paxillin family members function as Csk-binding proteins that regulate Lyn activity in human and murine platelets. *Biochem J*. 2007; 403:275–281. [PubMed: 17233630]
27. Jackson DE, Kupcho KR, Newman PJ. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2. *J Biol Chem*. 1997; 272:24868–24875. [PubMed: 9312087]
28. Tzeng SR, Pai MT, Lung FD, Wu CW, Roller PP, Lei B, Wei CJ, Tu SC, Chen SH, Soong WJ, Cheng JW. Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia. *Protein Sci*. 2000; 9:2377–2385. [PubMed: 11206059]
29. Ishino M, Aoto H, Sasaki H, Suzuki R, Sasaki T. Phosphorylation of Hic-5 at tyrosine 60 by CAK β and Fyn. *FEBS Lett*. 2000; 474:179–183. [PubMed: 10838081]
30. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9,

- CD33-related Siglecs expressed on human monocytes and NK cells. *J Immunol.* 2004; 173:6841–6849. [PubMed: 15557178]
31. Cicmil M, Thomas JM, Sage T, Barry FA, Leduc M, Bon C, Gibbins JM. Collagen, convulxin, and thrombin stimulate aggregation-independent tyrosine phosphorylation of CD31 in platelets. Evidence for the involvement of Src family kinases. *J Biol Chem.* 2000; 275:27339–27347. [PubMed: 10858437]
  32. Newman DK. The Y's that bind: negative regulators of Src family kinase activity in platelets. *J Thromb Haemost.* 2009; 7(Suppl 1):195–199. [PubMed: 19630799]
  33. Jackson DE, Ward CM, Wang R, Newman PJ. The protein-tyrosine phosphatase SHP-2 binds PECAM-1 and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1 and integrin-mediated cellular signaling. *J Biol Chem.* 1997; 272:6986–6993. [PubMed: 9054388]
  34. Pumphrey NJ, Taylor V, Freeman S, Douglas MR, Bradfield PF, Young SP, Lord JM, Wakelam MJ, Bird IN, Salmon M, Buckley CD. Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31. *Febs Lett.* 1999; 450:77–83. [PubMed: 10350061]
  35. Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56^{lck}. *Blood.* 2001; 97:2351–2357. [PubMed: 11290597]
  36. Henshall TL, Jones KL, Wilkinson R, Jackson DE. Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling. *J Immunol.* 2001; 166:3098–3106. [PubMed: 11207261]
  37. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. *Mol Cell.* 2004; 13:341–355. [PubMed: 14967142]
  38. Ren Y, Meng S, Mei L, Zhao ZJ, Jove R, Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. *J Biol Chem.* 2004; 279:8497–8505. [PubMed: 14665621]
  39. Joseph RE, Andreotti AH. Conformational snapshots of Tec kinases during signaling. *Immunol Rev.* 2009; 228:74–92. [PubMed: 19290922]
  40. Mohamed AJ, Nore BF, Christensson B, Smith CI. Signalling of Bruton's tyrosine kinase, Btk. *Scand J Immunol.* 1999; 49:113–118. [PubMed: 10075013]
  41. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. *Curr Biol.* 1998; 8:1137–1140. [PubMed: 9778529]
  42. Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. *Blood.* 2003
  43. Schmedt C, Saijo K, Niidome T, Kuhn R, Aizawa S, Tarakhovsky A. Csk controls antigen receptor-mediated development and selection of T-lineage cells. *Nature.* 1998; 394:901–904. [PubMed: 9732874]
  44. Rhee I, Veillette A. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. *Nat Immunol.* 2012; 13:439–447. [PubMed: 22513334]
  45. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. *Immunol Rev.* 2008; 224:70–84. [PubMed: 18759921]
  46. Daron M, Jaeger S, Du PL, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. *Immunol Rev.* 2008; 224:11–43. [PubMed: 18759918]

Figure 1. Lyn, but not Btk or Csk, phosphorylates the PECAM-1 C-terminal ITIM, which once phosphorylated enhances phosphorylation of the N-terminal ITIM by Lyn, Btk and Csk
 (A) Synthetic peptides corresponding to the N-terminal (Y₆₆₃) or C-terminal (Y₆₈₆) ITIM of PECAM-1 were incubated with Lyn (white bars), Btk (black bars), or Csk (gray bars) for 4 hours at 30°C, after which the amount of ADP generated was determined using an ADP Hunter kit. Results are expressed as the mean ADP concentration $\pm$ S.D. calculated from three independent experiments. Inset: Schematic representation of the sequences of the Y₆₆₃- or Y₆₈₆-containing peptides. (B) Synthetic PECAM-1 peptides that span both ITIMs and that contain a tyrosine residue within the N-terminal ITIM (Y₆₆₃) and either a phenylalanine (F₆₈₆) or a phosphotyrosine (pY₆₈₆) within the C-terminal ITIM were incubated with Lyn (white bar), Btk (black bar), or Csk (gray bar), after which ADP generation was measured. The ratio of the amount of ADP generated by each enzyme in the presence of Y₆₆₃,pY₆₈₆ vs. Y₆₆₃,F₆₈₆ was determined in three independent experiments. Results are expressed as the mean ratio of phosphorylation $\pm$ S.D. Inset: Schematic representation of the sequences of the PECAM-1 Y₆₆₃,F₆₈₆ and Y₆₆₃,pY₆₈₆-containing peptides.

Figure 2. Initial phosphorylation of PECAM-1 by Lyn enables subsequent phosphorylation by Btk and Csk

Purified, recombinant PECAM-1 cytoplasmic domain (PECAM-1_{cyto}) was incubated with no kinase (None) or subjected to a 10 minute incubation with Lyn alone (Lyn 10'), a 30 minute incubation with Lyn (Lyn - 30'), Btk (Btk - 30'), or Csk (Csk - 30'), or a 10 minute incubation with Lyn followed by heat-inactivation of Lyn (60°C, 20 min), and an additional 30 minute incubation with Lyn (Lyn → Lyn), Btk (Lyn → Btk), or Csk (Lyn → Csk). Phosphorylated PECAM-1_{cyto} species were separated by SDS-PAGE and stained with Coomassie blue. (A) Mono- and di-phosphorylated PECAM-1_{cyto} species migrated at a higher apparent molecular weight than non-phosphorylated PECAM-1_{cyto} with the di-phosphorylated species having a higher apparent molecular weight than the mono-phosphorylated species. The image shown is representative of four independent experiments. (B) Band intensities were quantified using a Kodak Molecular Imaging Densitometry System. Total band intensities (non-phospho + mono-phospho + di-phospho band intensities) were normalized to 100% for each lane. Results are expressed as the mean % of PECAM-1_{cyto} in the di-phosphorylated band relative to the total band intensity ± S.D. calculated from four independent experiments. (**p<.01, ***p<0.001) (C) PECAM-1_{cyto} with ITIM tyrosine residues mutated to phenylalanine (Y₆₆₃,F₆₈₆; F₆₆₃,Y₆₈₆) as well as WT PECAM-1_{cyto} (Y₆₆₃,Y₆₈₆) were incubated with Lyn alone or with Lyn followed by an additional incubation with either Btk or Csk. As described above the phosphorylated PECAM-1_{cyto} species generated during these reactions were separated by SDS-PAGE and stained with Coomassie blue. Data shown are representative of three independent experiments.

Figure 3. PECAM-1 is phosphorylated on its C-terminal ITIM but cannot bind SHP-2 in platelets activated in the presence of a PI3K inhibitor

Human platelets were activated with collagen-related peptide (CRP) in the presence and absence of a SHP-2 inhibitor and/or a PI3K inhibitor and then lysed as described in Materials and Methods. PECAM-1 was immunoprecipitated (IP) from platelet lysates. PECAM-1 IPs were probed by Western blot analysis using antibodies specific for phosphotyrosine (anti-pY), co-precipitating SHP-2 (anti-SHP-2) and PECAM-1 antigen (anti-PECAM-1). The data shown are representative of three independent experiments.

Figure 4. ITIM linkage in a single polypeptide is required for pY₆₈₆-dependent phosphorylation of Y₆₆₃ by Btk and Csk

Synthetic peptides corresponding to the N-terminal ITIM (Y₆₆₃) and the phosphorylated C-terminal ITIM (Y₆₈₆) of PECAM-1 were incubated with (A) Btk or (B) Csk either alone or in combination with each other as separate peptides (Y₆₆₃ + pY₆₈₆) or as parts of a single peptide corresponding to the portion of the PECAM-1 cytoplasmic domain that encompasses both ITIMs (Y₆₆₃:pY₆₈₆). Reactions were carried out over 4 hours at 30°C, after which ADP generation was measured. Results are expressed as the mean ADP concentration $\pm$ S.D. calculated from three independent experiments. (***) $p < 0.001$

Figure 5. Csk and Lyn, but not Btk, interact with the C-terminal ITIM of PECAM-1 via an SH2 domain-dependent interaction

(A) Polystyrene streptavidin beads coated with the PECAM-1 Y₆₆₃.pY₆₈₆ peptide were incubated with GST fusion proteins containing the SH2 domain of Btk (dashed line), Lyn (dotted line), or Csk (solid line), washed, and stained with an Alexa 647- conjugated GST-specific antibody. The relative ability of these SH2 domains to bind Y₆₆₃.pY₆₈₆ was measured by flow cytometry and reported as median fluorescence intensity (MFI). The negative control (Bkgnd; gray histogram) reflects the MFI observed upon binding of the SH2 domain of Btk to beads not coated with peptide; Csk and Lyn SH2 domains exhibited similar levels of background binding. Results shown are representative of three independent experiments. (B) Lysates of resting human platelets were incubated with streptavidin beads coated with PECAM-1 Y₆₆₃.F₆₈₆-or Y₆₆₃.pY₆₈₆-containing peptides. Whole platelet lysates and peptide-precipitates were separated by SDS-PAGE and probed by Western blot analysis using antibodies specific for Lyn (anti-Lyn), Btk (anti-Btk) and Csk (anti-Csk). The data shown are representative of three independent experiments.

Figure 6. Btk and Csk utilize their SH2 domains to direct them to phosphorylate Y₆₆₃ in a pY₆₈₆-dependent manner

(A and B) A biotinylated PECAM-1 peptide substrate (Y₆₆₃;pY₆₈₆; 10 μM) or (C and D) a biotinylated Poly (Glu₄-Tyr) peptide substrate (10 μM) incubated with 48 nM Btk (A and C) or Csk (B and D) in the presence and absence of unbiotinylated competitor peptides. Dose response studies (not shown) were performed to determine the concentrations of competitor peptides that inhibited phosphorylation of PECAM-1 Y₆₆₃;pY₆₈₆ by 50%. For the purposes of comparison, the concentrations of competitor peptides that decreased activity toward PECAM-1 Y₆₆₃;pY₆₈₆ by approximately 50% are shown. Competitor peptides corresponded to the phosphorylated C-terminal ITIM (pY₆₈₆) of PECAM-1, an SH2 domain optimal binding peptide (OBP) for either Btk (GDGpYEEISPLLL; Btk SH2 OBP) or Csk (DKDHLpYSTVCK; Csk SH2 OBP). After incubation for one hour at 37°C in the presence of [γ ³²P]ATP, biotinylated peptides were captured onto streptavidin beads and washed extensively. ³²P incorporation into captured peptides was quantified by scintillation counting of washed beads. Results are expressed as mean counts per minute (cpm) $\pm$ S.D. calculated from triplicate reactions with background subtracted. (**p<0.01, ***p<0.001, n.s.=not significant).

Figure 7. Csk requires the phosphotyrosine binding ability of its SH2 domain to effectively phosphorylate the N-terminal ITIM of PECAM-1 in the presence of the phosphorylated C-terminal ITIM

(A) Protein G-containing polystyrene beads coated with a Csk-specific antibody were used to capture wild-type (WT; dashed line), R₁₀₇K (dotted line), or S₁₀₉C (solid line) forms of recombinant Csk, after which beads were washed, incubated with biotinylated PECAM-1 Y₆₆₃,pY₆₈₆ peptides and stained with an Alexa 647-conjugated Streptavidin. The relative ability of WT and mutant forms of Csk to bind PECAM-1 Y₆₆₃,pY₆₈₆-containing peptides was measured by flow cytometry and reported as median fluorescence intensity (MFI). The negative control (Bkgrd; gray histogram) reflects the MFI observed in the absence of Csk. Results are representative of two independent experiments. (B) A biotinylated PECAM-1 peptide substrate (Y₆₆₃,pY₆₈₆ or Y₆₆₃,F₆₈₆; 50 μM) was incubated with wild-type (WT) or SH2 domain mutant (R₁₀₇K or S₁₀₉C) forms of GST-conjugated Csk for one hour at 37°C in the presence of [γ ³²P]ATP. ³²P incorporation into captured peptides was quantified by scintillation counting of washed beads. Results are expressed as the mean counts per minute (cpm) ± S.D. calculated from triplicate reactions with background (no peptide substrate) subtracted. The data shown are representative of 2 independent experiments (*p < 0.05, ***p < 0.001)

Figure 8. Prior phosphorylation of the C-terminal ITIM of Siglec 9 enhances phosphorylation of the N-terminal ITIM by Csk

Increasing concentrations of a biotinylated peptide substrate corresponding to the sequence of Siglec-9 that spans its two ITIMs ($\text{Y}_{416},\text{pY}_{439}$ or $\text{Y}_{416},\text{F}_{439}$) were incubated with Csk (48 nM) for one hour at 37°C in the presence of $[\gamma^{32}\text{P}]\text{ATP}$. ^{32}P incorporation into captured peptides was quantified by scintillation counting of washed beads. Results are expressed as mean counts per minute (cpm) $\pm$ S.D. calculated from triplicate reactions with background (no peptide substrate) subtracted. The data shown are representative of 2 independent experiments. ^{32}P incorporation into $\text{Y}_{416},\text{pY}_{439}$ peptides was significantly greater than that incorporated into $\text{Y}_{416},\text{F}_{439}$ peptides ($***p < 0.001$) at each concentration tested. Inset: Schematic representation of the sequences of the Siglec-9 $\text{Y}_{416},\text{pY}_{439}$ - or $\text{Y}_{416},\text{F}_{439}$ -containing peptides.

Figure 9. Schematic describing a novel mechanism for control of the timing of ITIM-mediated inhibition vs. ITAM-dependent activation

Following binding of collagen to GPVI, the SFK Lyn initiates both inhibitory and activating signaling pathways by phosphorylating the C-terminal ITIM (Y₆₈₆) of PECAM-1 and the ITAMs of the GPVI-associated FcR γ chain. Phosphorylation of PECAM-1 Y₆₈₆ (pY₆₈₆) is insufficient for inhibitory function, which requires that both ITIMs be phosphorylated. Phosphorylation of the FcR γ ITAMs enables recruitment of Syk, phosphorylation of the LAT/Gads/SLP-76 signalosome, activation of PI3K, and production of PIP₃, which support recruitment of PLC γ 2 and Btk to the plasma membrane. Btk phosphorylates PLC γ 2, which generates the second messengers DAG and IP₃ that are required for $\alpha_{IIb}\beta_3$ -dependent platelet aggregation. In aggregating platelets, Csk is recruited to the plasma membrane where it deactivates SFKs involved in GPVI signaling. Once recruited, Btk and Csk can phosphorylate pY₆₈₆-containing PECAM-1 on Y₆₆₃. Dual ITIM phosphorylation of PECAM-1 allows recruitment and activation of SHP-2, which is required for PECAM-1-mediated inhibitory function. The requirement for NRTKs recruited only very late in the process of ITAM-dependent activation to phosphorylate the second ITIM of a dual ITIM-containing inhibitory receptor provides a novel mechanism by which ITIM-mediated inhibitory function can be delayed relative to ITAM-mediated activation. Abbreviations: Btk, Bruton's tyrosine kinase; Csk, C-terminal Src kinase; DAG, diacylglycerol; FcR γ , Fc receptor γ -chain; Gads, GRB2-related adapter protein 2; GPVI, Glycoprotein VI; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibitory motif; IP₃, inositol (1,4,5)-trisphosphate; LAT, linker for activation of T cells;

Lyn, Lck/Yes-related novel protein tyrosine kinase; NRTKs, non-receptor tyrosine kinase; PECAM-1, Platelet endothelial cell adhesion molecule 1; PI3K, Phosphatidylinositol 3-kinase; PIP₃, phosphatidylinositol 3,4,5-trisphosphate; PLC γ 2, phospholipase C γ 2 isoform; SLP-76, Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa; SFK, Src family kinase; SHP-2, SH2 domain-containing protein tyrosine phosphatase 2; Syk, Spleen tyrosine kinase.